Since FGL1 is a newly identified immune checkpoint ligand (18) and inhibition of SIRT2 by AGK2 could decrease FGL1 levels in HCC cells, we then determined whether pretreatment of tumor cells with AGK2 would affect T cell activity. This evidence concerns the gene SIRT2 and hepatocellular carcinoma.